Rx Oversight Issues at Federal Workers’ Comp Program Endangered Patients, Audit Says

The failure of a federal workers’ compensation program to properly manage prescription drug use and costs resulted in approximately $321 million in overspending on medications and “claimants receiving thousands of inappropriate prescriptions and potentially lethal drugs” like fentanyl, according to a new report from a government watchdog agency.

The Office of Workers’ Compensation Program (OWCP) said in the report, which reviewed data from fiscal years 2015-2020, that its hiring of a PBM in 2021 will address many of the concerns identified by auditors. But one consultant who participated in the audit contends that move will “absolutely not” fix the myriad oversight issues that were uncovered. In addition, the PBM’s contract does not require it to share any drug rebates with the Federal Employees Compensation Act (FECA) program — which makes the program an “outlier” among other federal payers, Joseph Paduda tells AIS Health, a division of MMIT.

© 2024 MMIT
Leslie Small

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

audit-report
December 1

OIG Audits Add to Debate Over Extrapolation in Recovering MA Overpayments

READ MORE
audit
December 9

Federal Watchdogs Raise Telehealth Fraud Concerns

READ MORE
doctor-shaking-hands-with-a-serviceman
January 13

With New TRICARE Pacts, Defense Dept. Pledges to Learn From Past Contractor Squabbles

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today